Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | BCHE | P06276 | 5/20 | 0.43 |
| ▸ | HTR1A | P08908 | 1/20 | 0.41 |
| ▸ | HSPA5 | P11021 | 1/20 | 0.41 |
| ▸ | CA12 | O43570 | 4/20 | 0.40 |
| ▸ | CA2 | P00918 | 4/20 | 0.40 |
| ▸ | CA9 | Q16790 | 4/20 | 0.40 |
| ▸ | TSHR | P16473 | 2/20 | 0.37 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.37 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.37 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.37 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.37 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.36 |
| ▸ | ACHE | P22303 | 2/20 | 0.36 |
| ▸ | TAAR1 | Q96RJ0 | 1/20 | 0.36 |
| ▸ | AKR1B1 | P15121 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL20175934 | 0.87 | BCHE (0.45) | BCHEHTR1AHSD17B10ACHE | |
| SCHEMBL20175944 | 0.85 | MAPT (0.43) | BCHEHTR1AHSPA5HSD17B10ACHE | |
| SCHEMBL30589673 | 0.83 | SMN1; SMN2 (0.49) | HTR1AHSPA5CA12CA2CA9 | |
| SCHEMBL27910543 | 0.83 | HTR1A (0.53) | BCHEHTR1ATSHRACHE | |
| SCHEMBL9395374 | 0.81 | HSPA5 (0.54) | HTR1AHSPA5CA12CA2CA9 | |
| SCHEMBL20180914 | 0.80 | HSPA5 (0.48) | HTR1AHSPA5CA12CA2CA9 | |
| SCHEMBL20175945 | 0.79 | BCHE (0.42) | BCHEHTR1AACHE | |
| SCHEMBL10486437 | 0.79 | HTR1A (0.56) | BCHEHTR1AHSPA5TSHRACHE | |
| SCHEMBL20175937 | 0.78 | BCHE (0.40) | BCHEHTR1AACHE | |
| SCHEMBL15283002 | 0.77 | HSPA5 (0.59) | HTR1AHSPA5CA12CA2CA9 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10570104-B2 | Metabolically programmed metal chelators and uses thereof | UNIVERSITY OF FLORIDA RESEARCH FOUNDATION, INCORPORATED (US) | 2020-02-25 | — | — | US | disclosed |
| US-20180140581-A1 | METABOLICALLY PROGRAMMED METAL CHELATORS AND USES THEREOF | UNIVERSITY OF FLORIDA RESEARCH FOUNDATION, INCORPORATED (US) | 2018-05-24 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10570104-B2 | Metabolically programmed metal chelators and uses thereof | FECH, SLC19A1, SLC40A1 | BCHE 1142/4885HTR1A 1408/4885HSPA5 1233/4885 |
| US-20180140581-A1 | METABOLICALLY PROGRAMMED METAL CHELATORS AND USES THEREOF | FECH, SLC19A1, SLC40A1 | BCHE 1142/4885HTR1A 1408/4885HSPA5 1233/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.